InvestorsHub Logo
Followers 11
Posts 847
Boards Moderated 0
Alias Born 03/26/2011

Re: None

Thursday, 03/15/2018 11:18:22 AM

Thursday, March 15, 2018 11:18:22 AM

Post# of 92
Awesome news today!
AC Immune prepares for a first in human study of a promising positron emission tomography (PET) tracer for Parkinson's diseas...

>>> First potential PET tracer for Parkinson's disease
>>> First in human study is scheduled for the second half of 2018
>>> AC Immune's lead compound is highly selective for alpha-synuclein - a key protein in Parkinson's disease pathology


This next generation tracer was discovered using the company's proprietary MorphomerTM chemistry technology platform. AC Immune has been successfully collaborating on this program with Biogen since April 2016. The companies will continue to further research, develop and clinically validate this alpha-synuclein PET tracer that will be used as an imaging biomarker for Parkinson's disease with an aim to enable the clinical development of new disease-modifying therapies. This project from AC Immune is being supported by The Michael J. Fox Foundation for Parkinson's Research (MJFF).

https://ih.advfn.com/p.php?pid=nmona&article=76951663
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ACIU News